INMUNE BIO INC. - COMMON STOCK

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

11 Apr 2023 07:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

03 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

02 Mar 2023 15:05:52 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

08 Feb 2023 07:45:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

25 Jan 2023 06:45:00 By Nasdaq GlobeNewswire

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

22 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

08 Dec 2022 07:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

06 Dec 2022 15:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

14 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

02 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

26 Oct 2022 07:10:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

19 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference

07 Sep 2022 08:00:03 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

03 Aug 2022 15:10:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

27 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

25 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

16 Jun 2022 07:00:01 By Nasdaq GlobeNewswire